Nymox Pharmaceutical Corp (NYMX) 0.36 $NYMX
UPDATE - UPCOMING DEADLINE: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against Nymox Pharmaceutical Corporation and Its Board of Directors and a Lead Plaintiff Deadline of January 26, 2015
Business Wire - Tue Jan 20, 1:56PM CST
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Nymox Pharmaceutical Corporation ("Nymox" or the "Company"
(Nasdaq:NYMX) securities between January 31, 2011 and November 2, 2014.
NYMX: 0.36 (-0.02)
NYMOX SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $150,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Nymox Pharmaceutical Corporation - NYMX
GlobeNewswire - Mon Jan 19, 9:00PM CST
Kahn Swick & Foti, LLC ("KSF" and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until January 26, 2015 to file lead plaintiff applications in a securities class action lawsuit against Nymox Pharmaceutical Corporation (Nasdaq:NYMX) if they purchased the Company's securities between January 31, 2011 and November 2, 2014, inclusive (the "Class Period" . This action is pending in the United States District Court for the District of New Jersey.
NYMX: 0.36 (-0.02)
UPDATE -- UPCOMING DEADLINE: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against Nymox Pharmaceutical Corporation and Its Board of Directors and a Lead Plaintiff Deadline of January 26, 2015 -- NYMX
GlobeNewswire - Mon Jan 12, 4:33PM CST
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Nymox Pharmaceutical Corporation ("Nymox" or the "Company" (Nasdaq:NYMX) securities between January 31, 2011 and November 2, 2014.
NYMX: 0.36 (-0.02)
Rosen Law Firm Reminds Nymox Pharmaceutical Corporation Investors of Important January 26, 2015 Class Action Deadline -- NYMX
GlobeNewswire - Mon Jan 12, 2:09PM CST
The Rosen Law Firm reminds purchasers of Nymox Pharmaceutical Corporation common stock (Nasdaq:NYMX) during the period from January 31, 2011 through November 2, 2014, of the important January 26, 2015 lead plaintiff deadline in the class action.
NYMX: 0.36 (-0.02)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of Class Action Against Nymox Pharmaceutical Corporation and Its Board of Directors and a Lead Plaintiff Deadline of January 26, 2015 -- NYMX
PR Newswire - Fri Jan 02, 11:53AM CST
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Nymox Pharmaceutical Corporation ("Nymox" or the "Company" (Nasdaq: NYMX) securities between January 31, 2011 and November 2, 2014.
NYMX: 0.36 (-0.02)
Benign Prostatic Hyperplasia - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/nqt9vr/benign_prostatic) has announced the addition of the "Benign Prostatic Hyperplasia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Benign Prostatic Hyperplasia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Benign Prostatic Hyperplasia and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Benign Prostatic Hyperplasia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Benign Prostatic Hyperplasia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - AEterna Zentaris - Addex Therapeutics - AmVac - Aphios Corporation - Astellas Pharma Inc. - Ausio Pharmaceuticals - Biolab Sanus Farmaceutica - Chong Kun Dang Pharmaceutical - Chugai Pharmaceutical - Curadis GmbH - Euroscreen S.A. - Hanmi Pharmaceuticals - IntelGenx - KAEL-GemVax - Kaken Pharmaceutical - Mezzion Pharma - Nymox Pharmaceutical - Ono Pharmaceutical - Quest PharmaTech - SK Chemicals - SOM Biotech - Sophiris Bio - Yungjin Pharm For more information visit http://www.researchandmarkets.com/research/nq..._prostatic
SPHS: 0.44 (-0.01), AEZS: 0.53 (unch), NYMX: 0.36 (-0.02)
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Nymox Pharmaceutical Corporation To Contact Brower Piven Before The January 26, 2015 Lead Plaintiff Deadline In Class Action Lawsuit
Business Wire - Tue Dec 30, 7:00PM CST
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Nymox Pharmaceutical Corporation ("Nymox" or the "Company" (Nasdaq: NYMX) common stock during the period between January 31, 2011 and November 2, 2014, inclusive (the "Class Period" . Investors who wish to become proactively involved in the litigation have until January 26, 2015 to seek appointment as lead plaintiff.
NYMX: 0.36 (-0.02)
SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against Nymox Pharmaceutical Corporation and Its Board of Directors and a Lead Plaintiff Deadline of January 26, 2015
Business Wire - Mon Dec 29, 3:31PM CST
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Nymox Pharmaceutical Corporation ("Nymox" or the "Company" (Nasdaq:NYMX) securities between January 31, 2011 and November 2, 2014.
NYMX: 0.36 (-0.02)
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Nymox Pharmaceutical Corporation to Contact Brower Piven Before the January 26, 2015 Lead Plaintiff Deadline in Class Action Lawsuit -- NYMX
GlobeNewswire - Mon Dec 22, 7:18PM CST
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Nymox Pharmaceutical Corporation ("Nymox" or the "Company" (Nasdaq:NYMX) common stock during the period between January 31, 2011 and November 2, 2014, inclusive (the "Class Period" . Investors who wish to become proactively involved in the litigation have until January 26, 2015 to seek appointment as lead plaintiff.
NYMX: 0.36 (-0.02)
Nymox concludes USD1.07m convertible debenture financing
M2 - Fri Dec 19, 7:04AM CST
Biopharmaceutical company Nymox Pharmaceutical (NasdaqCM:NYMX) revealed on Thursday the completion of its USD1.07m financing, with Cantone Asset Management as the exclusive agent.
NYMX: 0.36 (-0.02)
Nymox Announces $1.07 Million Financing
GlobeNewswire - Thu Dec 18, 11:57AM CST
Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today the closing of U.S. $1.07 million in financing, consisting of a 3 year term convertible debenture at 6% with conversion at $0.53. The proceeds will be used as additional funding for the Company's activities in the next year. Cantone Asset Management LLC of Tintin Falls NJ served as exclusive agent for the convertible offering.
NYMX: 0.36 (-0.02)
EQUITY ALERT: Rosen Law Firm Reminds Nymox Pharmaceutical Corporation Investors of Important Class Action Deadline -- NYMX
GlobeNewswire - Fri Dec 12, 3:04PM CST
The Rosen Law Firm reminds purchasers of Nymox Pharmaceutical Corporation common stock (Nasdaq:NYMX) during the period from January 31, 2011 through November 2, 2014, of the important January 26, 2015 lead plaintiff deadline in the class action.
NYMX: 0.36 (-0.02)
SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against Nymox Pharmaceutical Corporation and Its Board of Directors and a Lead Plaintiff Deadline of January 26, 2015 -- NYMX
GlobeNewswire - Thu Dec 11, 2:09PM CST
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Nymox Pharmaceutical Corporation ("Nymox" or the "Company" (Nasdaq:NYMX) securities between January 31, 2011 and November 2, 2014.
NYMX: 0.36 (-0.02)
Law Offices of Marc S. Henzel Announces Securities Class Action Periods
PR Newswire - Mon Dec 08, 8:11AM CST
The Law Offices of Marc S. Henzel (www.henzellaw.com) a firm focusing on shareholder litigation, gives notice to purchasers of the following securities for the following class periods:
MOLG: 2.46 (+0.03), AVNR: 16.96 (unch), HE: 33.14 (-0.22), ADHD: 6.92 (+0.73), NYMX: 0.36 (-0.02), SDRL: 12.32 (-0.70), SNY: 49.42 (+0.82), AMRI: 16.94 (-0.28), CIE: 8.90 (+0.20)
Escherichia Coli Infections - Pipeline Review, H2 2014
M2 - Mon Dec 08, 4:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/dtjjhp/escherichia_coli) has announced the addition of the "Escherichia Coli Infections - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Escherichia Coli Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Escherichia Coli Infections and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Escherichia Coli Infections - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Escherichia Coli Infections pipeline depth and focus of Indication therapeutics Companies Mentioned: - Adenium Biotech ApS - Arsanis Biosciences GmbH - AvidBiotics Corp. - Bellus Health Inc. - Bioorganic Research and Services S.A. - Cellceutix Corporation - Chiesi Farmaceutici SpA - ConjuGon, Inc. - Debiopharm International S.A. - Evolva SA - GangaGen Inc. - Genentech, Inc. - GlycoVaxyn AG - Immuron Limited - Melinta Therapeutics, Inc - Northern Antibiotics Oy - Nosopharm SAS - NovaBay Pharmaceuticals, Inc. - Novabiotics Ltd - Nymox Pharmaceutical Corporation - Pherecydes Pharma SA - Phico Therapeutics Ltd. - Procarta Biosystems Ltd - Sanofi Pasteur SA - Sealife PHARMA GMBH - Sequoia Sciences, Inc. - Soligenix, Inc. - Spider Biotech - Syntiron LLC - Trana Discovery, Inc. For more information visit http://www.researchandmarkets.com/research/dt...ichia_coli
NYMX: 0.36 (-0.02)
Lifshitz & Miller Law Firm Announces Investigation of Avanir Pharmaceuticals, Inc., Carbonite, Inc., Casey's General Stores, Inc., Nymox Pharmaceutical Corporation, Puma Biotechnology Inc., RealD Inc., and Spansion, Inc.
PR Newswire - Thu Dec 04, 12:21PM CST
Avanir Pharmaceuticals, Inc.
CARB: 14.96 (+0.07), AVNR: 16.96 (unch), RLD: 12.65 (+0.16), NYMX: 0.36 (-0.02), CASY: 88.93 (-1.10), PBYI: 205.26 (+2.75), CODE: 35.99 (+0.03)
Robbins Arroyo LLP: Nymox Pharmaceutical Corporation (NYMX) Misled Shareholders According to a Recently Filed Class Action
GlobeNewswire - Mon Dec 01, 7:07PM CST
Shareholder rights law firm Robbins Arroyo LLP announces that an investor of Nymox Pharmaceutical Corporation (Nasdaq:NYMX) has filed a federal securities fraud class action complaint in the U.S. District Court for the Southern District of New Jersey. The complaint alleges that the company and certain of its officers and directors violated the Securities Act of 1934 in connection with Nymox's misstatements regarding the viability of its proprietary drug NX-1207 for the treatment of benign prostatic hyperplasia ("BPH" . Nymox is engaged in the research and development of therapeutics and diagnostics, with an emphasis on products for the unmet needs of the aging population.
NYMX: 0.36 (-0.02)
Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Nymox Pharmaceutical Corporation -- NYMX
GlobeNewswire - Wed Nov 26, 6:00PM CST
Gainey McKenna & Egleston announces that a class action lawsuit has been filed in the United States District Court for the District of New Jersey, on behalf of all persons who purchased or otherwise acquired Nymox Pharmaceutical Corporation ("Nymox" or the "Company" (Nasdaq:NYMX) securities during the period between January 31, 2011 through November 2, 2014, inclusive (the "Class Period" . This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act" .
NYMX: 0.36 (-0.02)
UPDATE - UPCOMING DEADLINE: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against Nymox Pharmaceutical Corporation and Its Board of Directors and a Lead Plaintiff Deadline of January 26, 2015
Business Wire - Tue Jan 20, 1:56PM CST
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Nymox Pharmaceutical Corporation ("Nymox" or the "Company"
(Nasdaq:NYMX) securities between January 31, 2011 and November 2, 2014. NYMX: 0.36 (-0.02)
NYMOX SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $150,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Nymox Pharmaceutical Corporation - NYMX
GlobeNewswire - Mon Jan 19, 9:00PM CST
Kahn Swick & Foti, LLC ("KSF"
and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until January 26, 2015 to file lead plaintiff applications in a securities class action lawsuit against Nymox Pharmaceutical Corporation (Nasdaq:NYMX) if they purchased the Company's securities between January 31, 2011 and November 2, 2014, inclusive (the "Class Period" . This action is pending in the United States District Court for the District of New Jersey. NYMX: 0.36 (-0.02)
UPDATE -- UPCOMING DEADLINE: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against Nymox Pharmaceutical Corporation and Its Board of Directors and a Lead Plaintiff Deadline of January 26, 2015 -- NYMX
GlobeNewswire - Mon Jan 12, 4:33PM CST
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Nymox Pharmaceutical Corporation ("Nymox" or the "Company"
(Nasdaq:NYMX) securities between January 31, 2011 and November 2, 2014. NYMX: 0.36 (-0.02)
Rosen Law Firm Reminds Nymox Pharmaceutical Corporation Investors of Important January 26, 2015 Class Action Deadline -- NYMX
GlobeNewswire - Mon Jan 12, 2:09PM CST
The Rosen Law Firm reminds purchasers of Nymox Pharmaceutical Corporation common stock (Nasdaq:NYMX) during the period from January 31, 2011 through November 2, 2014, of the important January 26, 2015 lead plaintiff deadline in the class action.
NYMX: 0.36 (-0.02)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of Class Action Against Nymox Pharmaceutical Corporation and Its Board of Directors and a Lead Plaintiff Deadline of January 26, 2015 -- NYMX
PR Newswire - Fri Jan 02, 11:53AM CST
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Nymox Pharmaceutical Corporation ("Nymox" or the "Company"
(Nasdaq: NYMX) securities between January 31, 2011 and November 2, 2014. NYMX: 0.36 (-0.02)
Benign Prostatic Hyperplasia - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/nqt9vr/benign_prostatic) has announced the addition of the "Benign Prostatic Hyperplasia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Benign Prostatic Hyperplasia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Benign Prostatic Hyperplasia and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Benign Prostatic Hyperplasia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Benign Prostatic Hyperplasia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - AEterna Zentaris - Addex Therapeutics - AmVac - Aphios Corporation - Astellas Pharma Inc. - Ausio Pharmaceuticals - Biolab Sanus Farmaceutica - Chong Kun Dang Pharmaceutical - Chugai Pharmaceutical - Curadis GmbH - Euroscreen S.A. - Hanmi Pharmaceuticals - IntelGenx - KAEL-GemVax - Kaken Pharmaceutical - Mezzion Pharma - Nymox Pharmaceutical - Ono Pharmaceutical - Quest PharmaTech - SK Chemicals - SOM Biotech - Sophiris Bio - Yungjin Pharm For more information visit http://www.researchandmarkets.com/research/nq..._prostatic
SPHS: 0.44 (-0.01), AEZS: 0.53 (unch), NYMX: 0.36 (-0.02)
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Nymox Pharmaceutical Corporation To Contact Brower Piven Before The January 26, 2015 Lead Plaintiff Deadline In Class Action Lawsuit
Business Wire - Tue Dec 30, 7:00PM CST
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Nymox Pharmaceutical Corporation ("Nymox" or the "Company"
(Nasdaq: NYMX) common stock during the period between January 31, 2011 and November 2, 2014, inclusive (the "Class Period" . Investors who wish to become proactively involved in the litigation have until January 26, 2015 to seek appointment as lead plaintiff. NYMX: 0.36 (-0.02)
SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against Nymox Pharmaceutical Corporation and Its Board of Directors and a Lead Plaintiff Deadline of January 26, 2015
Business Wire - Mon Dec 29, 3:31PM CST
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Nymox Pharmaceutical Corporation ("Nymox" or the "Company"
(Nasdaq:NYMX) securities between January 31, 2011 and November 2, 2014. NYMX: 0.36 (-0.02)
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Nymox Pharmaceutical Corporation to Contact Brower Piven Before the January 26, 2015 Lead Plaintiff Deadline in Class Action Lawsuit -- NYMX
GlobeNewswire - Mon Dec 22, 7:18PM CST
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Nymox Pharmaceutical Corporation ("Nymox" or the "Company"
(Nasdaq:NYMX) common stock during the period between January 31, 2011 and November 2, 2014, inclusive (the "Class Period" . Investors who wish to become proactively involved in the litigation have until January 26, 2015 to seek appointment as lead plaintiff. NYMX: 0.36 (-0.02)
Nymox concludes USD1.07m convertible debenture financing
M2 - Fri Dec 19, 7:04AM CST
Biopharmaceutical company Nymox Pharmaceutical (NasdaqCM:NYMX) revealed on Thursday the completion of its USD1.07m financing, with Cantone Asset Management as the exclusive agent.
NYMX: 0.36 (-0.02)
Nymox Announces $1.07 Million Financing
GlobeNewswire - Thu Dec 18, 11:57AM CST
Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today the closing of U.S. $1.07 million in financing, consisting of a 3 year term convertible debenture at 6% with conversion at $0.53. The proceeds will be used as additional funding for the Company's activities in the next year. Cantone Asset Management LLC of Tintin Falls NJ served as exclusive agent for the convertible offering.
NYMX: 0.36 (-0.02)
EQUITY ALERT: Rosen Law Firm Reminds Nymox Pharmaceutical Corporation Investors of Important Class Action Deadline -- NYMX
GlobeNewswire - Fri Dec 12, 3:04PM CST
The Rosen Law Firm reminds purchasers of Nymox Pharmaceutical Corporation common stock (Nasdaq:NYMX) during the period from January 31, 2011 through November 2, 2014, of the important January 26, 2015 lead plaintiff deadline in the class action.
NYMX: 0.36 (-0.02)
SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against Nymox Pharmaceutical Corporation and Its Board of Directors and a Lead Plaintiff Deadline of January 26, 2015 -- NYMX
GlobeNewswire - Thu Dec 11, 2:09PM CST
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Nymox Pharmaceutical Corporation ("Nymox" or the "Company"
(Nasdaq:NYMX) securities between January 31, 2011 and November 2, 2014. NYMX: 0.36 (-0.02)
Law Offices of Marc S. Henzel Announces Securities Class Action Periods
PR Newswire - Mon Dec 08, 8:11AM CST
The Law Offices of Marc S. Henzel (www.henzellaw.com) a firm focusing on shareholder litigation, gives notice to purchasers of the following securities for the following class periods:
MOLG: 2.46 (+0.03), AVNR: 16.96 (unch), HE: 33.14 (-0.22), ADHD: 6.92 (+0.73), NYMX: 0.36 (-0.02), SDRL: 12.32 (-0.70), SNY: 49.42 (+0.82), AMRI: 16.94 (-0.28), CIE: 8.90 (+0.20)
Escherichia Coli Infections - Pipeline Review, H2 2014
M2 - Mon Dec 08, 4:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/dtjjhp/escherichia_coli) has announced the addition of the "Escherichia Coli Infections - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Escherichia Coli Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Escherichia Coli Infections and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Escherichia Coli Infections - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Escherichia Coli Infections pipeline depth and focus of Indication therapeutics Companies Mentioned: - Adenium Biotech ApS - Arsanis Biosciences GmbH - AvidBiotics Corp. - Bellus Health Inc. - Bioorganic Research and Services S.A. - Cellceutix Corporation - Chiesi Farmaceutici SpA - ConjuGon, Inc. - Debiopharm International S.A. - Evolva SA - GangaGen Inc. - Genentech, Inc. - GlycoVaxyn AG - Immuron Limited - Melinta Therapeutics, Inc - Northern Antibiotics Oy - Nosopharm SAS - NovaBay Pharmaceuticals, Inc. - Novabiotics Ltd - Nymox Pharmaceutical Corporation - Pherecydes Pharma SA - Phico Therapeutics Ltd. - Procarta Biosystems Ltd - Sanofi Pasteur SA - Sealife PHARMA GMBH - Sequoia Sciences, Inc. - Soligenix, Inc. - Spider Biotech - Syntiron LLC - Trana Discovery, Inc. For more information visit http://www.researchandmarkets.com/research/dt...ichia_coli
NYMX: 0.36 (-0.02)
Lifshitz & Miller Law Firm Announces Investigation of Avanir Pharmaceuticals, Inc., Carbonite, Inc., Casey's General Stores, Inc., Nymox Pharmaceutical Corporation, Puma Biotechnology Inc., RealD Inc., and Spansion, Inc.
PR Newswire - Thu Dec 04, 12:21PM CST
Avanir Pharmaceuticals, Inc.
CARB: 14.96 (+0.07), AVNR: 16.96 (unch), RLD: 12.65 (+0.16), NYMX: 0.36 (-0.02), CASY: 88.93 (-1.10), PBYI: 205.26 (+2.75), CODE: 35.99 (+0.03)
Robbins Arroyo LLP: Nymox Pharmaceutical Corporation (NYMX) Misled Shareholders According to a Recently Filed Class Action
GlobeNewswire - Mon Dec 01, 7:07PM CST
Shareholder rights law firm Robbins Arroyo LLP announces that an investor of Nymox Pharmaceutical Corporation (Nasdaq:NYMX) has filed a federal securities fraud class action complaint in the U.S. District Court for the Southern District of New Jersey. The complaint alleges that the company and certain of its officers and directors violated the Securities Act of 1934 in connection with Nymox's misstatements regarding the viability of its proprietary drug NX-1207 for the treatment of benign prostatic hyperplasia ("BPH"
. Nymox is engaged in the research and development of therapeutics and diagnostics, with an emphasis on products for the unmet needs of the aging population. NYMX: 0.36 (-0.02)
Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Nymox Pharmaceutical Corporation -- NYMX
GlobeNewswire - Wed Nov 26, 6:00PM CST
Gainey McKenna & Egleston announces that a class action lawsuit has been filed in the United States District Court for the District of New Jersey, on behalf of all persons who purchased or otherwise acquired Nymox Pharmaceutical Corporation ("Nymox" or the "Company"
(Nasdaq:NYMX) securities during the period between January 31, 2011 through November 2, 2014, inclusive (the "Class Period" . This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act" . NYMX: 0.36 (-0.02)
